Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
123I-MIBG Scintigraphy for Neuroendocrine Tumors
NCT01373736Phase 3Unknown
- Sponsor
- Vancouver Coastal Health
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iobenguane I-123 in pheochromocytoma, neuroblastoma, Paraganglioma (PGL), medullary thyroid carcinoma (MTC), Carcinoid Tumor (CT), sponsored by Vancouver Coastal Health. Status: unknown.
02
Drugs
Iobenguane I-123
03
Conditions
pheochromocytomaneuroblastomaParaganglioma (PGL)medullary thyroid carcinoma (MTC)Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT01373736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01373736.